Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naive Subjects Infected With Hepatitis C Virus Genotype 1.

Trial Profile

Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naive Subjects Infected With Hepatitis C Virus Genotype 1.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Asunaprevir (Primary) ; Beclabuvir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2014 Results from patients with genotype 4 hepatitis C will be presented at The International Liver Congress, the 49th annual meeting of the European Association for the Study of the Liver (EASL) according to a Bristol-Myers Squibb media release.
    • 06 Mar 2014 Interim results in genotype 1 patients (n=166) presented at the 21st Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top